EssexBio

Essex-Bio Group

简繁 EN

ANNOUNCEMENTS & SHAREHOLDER INFORMATION

Normative Disclosure, Honest Communication

Select category

ANNOUNCEMENTS SHAREHOLDER INFORMATION

Select time

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012

Date

Title

File

Times

2025-04-03

NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM - NOTICE OF PUBLICATION OF CORPORATE COMMUNICATIONS

70

2025-04-03

NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM - NOTICE OF PUBLICATION OF CORPORATE COMMUNICATIONS

55

2025-04-03

NOTICE OF ANNUAL GENERAL MEETING

50

2025-04-03

FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, 21 MAY 2025 (or any adjournment thereof)

46

2025-04-03

PROPOSALS FOR GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES, RE-ELECTION OF DIRECTORS, AMENDMENTS TO ARTICLES OF ASSOCIATION, ADOPTION OF THE AMENDED AND RESTATED ARTICLES OF ASSOCIATION AND NOTICE OF ANNUAL GENERAL MEETING

50

2025-04-02

INSIDE INFORMATION A PHASE 3 CLINICAL STUDY IN RELATION TO THE CO-DEVELOPMENT OF THE LICENSED PRODUCT WITH HENLIUS FOR THE TREATMENT OF EXUDATIVE (WET) AGE-RELATED MACULAR DEGENERATION MET THE STUDY PRIMARY ENDPOINT

57

2025-04-02

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2025

57

2025-04-01

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND PROPOSED ADOPTION OF THE AMENDED AND RESTATED ARTICLES OF ASSOCIATION

61

2025-03-26

FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2024

93

2025-03-26

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024

122

2025-03-14

NOTICE OF BOARD MEETING

148

2025-03-04

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2025

153

2025-02-26

NEXT DAY DISCLOSURE RETURN

179

2025-02-10

NEXT DAY DISCLOSURE RETURN

240

2025-02-07

NEXT DAY DISCLOSURE RETURN

239

2025-02-04

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2025

227

2025-01-27

NEXT DAY DISCLOSURE RETURN

252

2025-01-13

NEXT DAY DISCLOSURE RETURN

280

2025-01-08

NEXT DAY DISCLOSURE RETURN

304

2025-01-06

LAST PATIENT LAST VISIT (LPLV) COMPLETED IN AN INTERNATIONAL MULTI-CENTRE PHASE 3 CLINICAL STUDY IN RELATION TO THE CO-DEVELOPMENT OF THE LICENSED PRODUCT WITH HENLIUS FOR THE TREATMENT OF EXUDATIVE (WET) AGE-RELATED MACULAR DEGENERATION

290

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT